Dermagnostix Revenue and Competitors
Employee Data
- Dermagnostix has 36 Employees.
- Dermagnostix grew their employee count by 57% last year.
Dermagnostix's People
Name | Title | Email/Phone |
---|
Dermagnostix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15M | 58 | -15% | N/A | N/A |
#2 | $7.5M | 774 | 21% | N/A | N/A |
#3 | N/A | 36 | 57% | N/A | N/A |
#4 | N/A | 83 | 19% | N/A | N/A |
#5 | N/A | 111 | 29% | N/A | N/A |
#6 | N/A | 64 | 33% | N/A | N/A |
#7 | N/A | 15 | 7% | N/A | N/A |
#8 | N/A | 52 | -26% | N/A | N/A |
#9 | N/A | 65 | 97% | N/A | N/A |
#10 | N/A | 29 | 0% | N/A | N/A |
What Is Dermagnostix?
At Dermagnostix, we develop groundbreaking diagnostics for dermatology to advance clinical practice and improve patients’ lives.\n\nWhy dermatology?\n•\tOne third of the population suffers from at least one skin condition – with a strong upward trend.\n•\tSkin diseases impair patients’ quality of life more drastically than cancer and diabetes.\n•\tBiologicals and small-molecule inhibitors have created an unprecedented potential for precision medicine. Diagnostics is lagging behind.\n\nOur solution?\n\nGroundbreaking translational research meets cutting-edge technology:\nDermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX, Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema.\nGet diagnostic support for hard-to-tackle skin diseases using our simple and fast system: Sample in – Answer out.\n\nwww.dermagnostix.com
keywords:N/AN/A
Total Funding
36
Number of Employees
N/A
Revenue (est)
57%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10M | 38 | 41% | N/A |
#2 | $4.4M | 38 | N/A | N/A |
#3 | N/A | 40 | 48% | N/A |
#4 | $5.6M | 48 | 0% | N/A |
#5 | N/A | 57 | 27% | N/A |